Endothelin: 20 Years from discovery to therapy

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 8, 2008, Pages 485-498

  Barton, Matthias ^a   Yanagisawa, Masashi ^b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Ambrisentan; Atherosclerosis; Bosentan; Congestive heart failure; Connective tissue disease; Darusentan; Diabetes; Diabetic nephropathy; Endothelin receptor antagonists; Kidney disease; Metabolic syndrome; Pulmonary hypertension; Scleroderma; Sitaxsentan

Indexed keywords

AMBRISENTAN; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRASENTAN; AVOSENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; LETAIRIS; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TEZOSENTAN; UNCLASSIFIED DRUG; ZD 4045;

ANTIHYPERTENSIVE ACTIVITY; AUTOIMMUNE DISEASE; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EDEMA; ESSENTIAL HYPERTENSION; FLUID RETENTION; HUMAN; KIDNEY DISEASE; LIVER CIRRHOSIS; NEOPLASM; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT SELECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ENDOTHELINS; HISTORY, 20TH CENTURY; HUMANS; RECEPTORS, ENDOTHELIN;

EID: 48849094089     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-059     Document Type: Review

References (176)

1. Agui, T., Xin, X., Cai, Y., Sakai, T., and Matsumoto, K. 1994. Stimulation of interleukin-6 production by endothelin in rat bone marrow-derived stromal cells. Blood, 84: 2531-2538. PMID:7919371.
2. Arai, H., Hori, S., Aramori, I., Ohkubo, H., and Nakanishi, S. 1990. Cloning and expression of a cDNA encoding an endothelin receptor. Nature, 348: 730-732. doi:10.1038/348730a0. PMID:2175396.
3. Bagnato, A., Spinella, F., and Rosanò, L. 2008. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can. J. Physiol. Pharmacol. 86: 473-484. doi:10.1139/Y08-058.
4. Barton, M. 2000. Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr. Hypertens. Rep. 2: 84-91. doi:10.1007/s11906-000-0064-5. PMID:10981133.
5. Barton, M. 2008. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat. Clin. Pract. Nephrol. In press. doi:10.1038/ ncpneph0891. PMID:18648345.
6. Barton, M., and Kiowski, W. 2001. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Curr. Hypertens. Rep. 3: 322-330. doi:10.1007/s11906-001-0095-6. PMID:11470015.
7. Barton, M., and Luscher, T.F. 1999. Endothelin antagonists for hypertension and renal disease. Curr. Opin. Nephrol. Hypertens. 8: 549-556. doi:10.1097/00041552-199909000-00003. PMID:10541216.
8. A receptors for endothelin regulation. Biochem. Biophys. Res. Commun. 238: 861-865. doi:10.1006/bbrc.1997.7394. PMID:9325182.
9. A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 95: 14367-14372. doi:10.1073/pnas.95.24.14367. PMID:9826706.
10. Barton, M., Lüscher, T.F., and Rabelink, T.J. 1998b. Salt Wars. On "The (political) science of salt". Science, 281: 1962. (Letter). doi:10.1126/science.281.5385.1986.
11. Barton, M., Carmona, R., Morawietz, H., d'Uscio, L.V., Goettsch, W., Hillen, H., et al. 2000a. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension, 35: 329-336. PMID:10642320.
12. Barton, M., Vos, I., Shaw, S., Boer, P., d'Uscio, L.V., Grone, H.J., et al. 2000b. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J. Am. Soc. Nephrol. 11: 835-845. PMID:10770961.
13. Barton, M., Carmona, R., Ortmann, J., Krieger, J.E., and Traupe, T. 2003. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int. J. Biochem. Cell Biol. 35: 826-837. doi:10.1016/S1357-2725(02)00307-2. PMID:12676169.
14. Barton, M., Mullins, J.J., Bailey, M.A., and Kretzler, M. 2006. Role of endothelin receptors for renal protection and survival in hypertension: waiting for clinical trials. Hypertension, 48: 834-837. doi:10.1161/01.HYP. 0000245138.09687.8a. PMID:17015776.
15. Battistini, B., Berthiaume, N., Kelland, N.F., Webb, D.J., and Kohan, D.E. 2006. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp. Biol. Med. (Maywood), 231: 653-695. PMID:16740981.
16. Benigni, A. 2000. Endothelin antagonists in renal disease. Kidney Int. 57: 1778-1794. doi:10.1046/j.1523-1755.2000.00023.x. PMID:10760116.
17. Benigni, A., and Remuzzi, G. 1999. Endothelin antagonists. Lancet, 353: 133-138. doi:10.1016/S0140-6736(98)09423-9. PMID:10023915.
18. Benigni, A., Zoja, C., Corna, D., Orisio, S., Longaretti, L., Bertani, T., and Remuzzi, G. 1993. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 44: 440-444. doi:10.1038/ki.1993.263. PMID:8377387.
19. Benigni, A., Perico, N., and Remuzzi, G. 2001. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Curr. Opin. Nephrol. Hypertens. 10: 1-6. doi:10.1097/00041552-200101000-00001. PMID:11195041.
20. Berthiaume, N., Carlson, C.J., Rondinone, C.M., and Zinker, B.A. 2005. Endothelin antagonism improves hepatic insulin sensitivity associated with insulin signaling in Zucker fatty rats. Metabolism, 54: 1515-1523. doi:10.1016/j.metabol.2005.05.019. PMID:16253642.
21. Bhattacharya, I., and Ullrich, A. 2006. Endothelin-1 inhibits adipogenesis: role of phosphorylation of Akt and ERK1/2. FEBS Lett. 580: 5765-5771. doi:10.1016/j.febslet.2006.09.032. PMID:17022980.
22. Black, H.R., Bakris, G.L., Weber, M.A., Weiss, R., Shahawy, M.E., Marple, R., et al. 2007. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J. Clin. Hypertens. (Greenwich), 9: 760-769. doi:10.1111/j.1524-6175.2007.07244.x. PMID:17917503.
23. Boffa, J.J., Tharaux, P.L., Dussaule, J.C., and Chatziantoniou, C. 2001. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension, 37: 490-496. PMID:11230324.
24. Bramall, A.N., Han, R.N., Deng, Y., Yanagisawa, M., McInnes, R.R., and Stewart, D.J. 2007. Endothelin 2 (ET-2) plays a critical role in lung alveolarization: novel insight from the ET-2-deficient mouse model. 10th International Conference on Endothelin. Bergamo, Italy. 16-19 September 2007. Abstract O-31. Available from http://www.et-10.it/docs/Abstracts_ET10.pdf. [Accessed 29 May 2008.]
25. Braun, C., Conzelmann, T., Vetter, S., Schaub, M., Back, W.E., Yard, B., et al. 1999. Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist. Transplantation, 68: 739-746. doi:10.1097/00007890-199909270-00005. PMID:10515373.
26. Bruno, S., Cattaneo, D., Perico, N., and Remuzzi, G. 2005. Emerging drugs for diabetic nephropathy. Expert Opin. Emerg. Drugs, 10: 747-771. doi:10.1517/14728214.10.4.747. PMID:16262561.
27. Bruzzi, I., Remuzzi, G., and Benigni, A. 1997. Endothelin: a mediator of renal disease progression. J. Nephrol. 10: 179-183. PMID:9377723.
28. Burke, G.W., Ciancio, G., Cirocco, R., Markou, M., Roth, D., Esquenazi, V., et al. 1998. Tacrolimus-related microangiopathy in kidney and simultaneous pancreas-kidney recipients: evidence of endothelin and cytokine involvement. Transplant. Proc. 30: 661-662. doi:10.1016/S0041-1345(97)01452-8. PMID:9532223.
29. Caligiuri, G., Levy, B., Pernow, J., Thoren, P., and Hansson, G.K. 1999. Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc. Natl. Acad. Sci. U.S.A. 96: 6920-6924. doi:10.1073/pnas.96.12.6920. PMID:10359814.
30. A endothelin receptors during the acute phase of Trypanosoma cruzi infection in rats. Microbes Infect. 6: 650-656. doi:10.1016/j.micinf.2004.03.002. PMID:15158772.
31. Cardillo, C., Campia, U., Iantorno, M., and Panza, J.A. 2004. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension, 43: 36-40. doi:10.1161/01.HYP.0000103868.45064.81. PMID:14656951.
32. Carrier, M., Tronc, F., Stewart, D., and Pelletier, L.C. 1991. Dose-dependent effect of cyclosporin on renal arterial resistance in dogs. Am. J. Physiol. 261: H1791-H1796. PMID:1661090.
33. Cauduro, R.L., Costa, C., Lhulier, F., Garcia, R.G., Cabral, R.D., Goncalves, L.F., and Manfro, R.C. 2005. Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin. Transplant. 19: 470-474. doi:10.1111/j.1399-0012.2005.00357.x. PMID:16008590.
34. Cernacek, P., Stewart, D.J., Monge, J.C., and Rouleau, J.L. 2003. The endothelin system and its role in acute myocardial infarction. Can. J. Physiol. Pharmacol. 81: 598-606. doi:10.1139/y03-052. PMID:12839271.
35. Chang, I., Williams, C., Baynach, A., Skatch, A., and Yanagisawa, M. 2007. Being starved and cold: the life without endothelin-2. 10th International Conference on Endothelin. Bergamo, Italy. 16-19 September 2007. Abstract O-12. Available from http://www.et-10.it/docs/Abstracts_ET10.pdf. [Accessed 29 May 2008.]
36. Channick, R.N., Simonneau, G., Sitbon, O., Robbins, I.M., Frost, A., Tapson, V.F., et al. 2001. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, 358: 1119-1123. doi:10.1016/S0140- 6736(01)06250-X. PMID:11597664.
37. Chatziantoniou, C., and Dussaule, J.C. 2005. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am. J. Physiol. Renal Physiol. 289: F227-F234. doi:10.1152/ajprenal.00453.2004. PMID:16006588.
38. Collino, F., Bussolati, B., Gerbaudo, E., Marozio, L., Pelissetto, S., Benedetto, C., and Camussi, G. 2008. Pre-eclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am. J. Physiol. Renal Physiol. 294: F1185-F1194. doi:10.1152/ajprenal.00442. 2007. PMID:18287402.
39. Cowburn, P.J., and Cleland, J.G. 2001. Endothelin antagonists for chronic heart failure: do they have a role? Eur. Heart J. 22: 1772-1784. doi:10.1053/euhj.2000.2557. PMID:11549299.
40. A-receptor antagonist, in chronic heart failure. Lancet, 352: 201-202. doi:10.1016/S0140-6736(05)77807-7. PMID:9683214.
41. Davenport, A.P. 2002. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev. 54: 219-226. doi:10.1124/pr.54.2.219. PMID:12037137.
42. De Mey, J.G., Claeys, M., and Vanhoutte, P.M. 1982. Endothelium-dependent inhibitory effects of acetylcholine, adenosine diphosphate, thrombin and arachidonic acid in the canaine femoral artery. J. Pharmacol. Exp. Ther. 222: 166-173. PMID:6806467.
43. Denton, C.P. 2007. Therapeutic targets in systemic sclerosis. Arthritis Res. Ther. 9(Suppl 2): S6. doi:10.1186/ar2190. PMID:17767744.
44. Denton, C.P., and Black, C.M. 2003. Pulmonary hypertension in systemic sclerosis. Rheum. Dis. Clin. North Am. 29: 335-349, vii. doi:10.1016/S0889-857X(03)00024-3. PMID:12841298.
45. Denton, C.P., Humbert, M., Rubin, L., and Black, C.M. 2006. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheum. Dis. 65: 1336-1340. doi:10.1136/ard.2005.048967. PMID:16793845.
46. Dubin, D., Pratt, R.E., Cooke, J.P., and Dzau, V.J. 1989. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J. Vasc. Med. Biol. 1: 13-17.
47. Dupuis, J. 2000. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. Can. J. Cardiol. 16: 903-910. PMID:10934309.
48. Dupuis, J. 2001. Endothelin-receptor antagonists in pulmonary hypertension. Lancet, 358: 1113-1114. doi:10.1016/S0140-6736(01)06298-5. PMID:11597660.
49. Duru, F., Barton, M., Luscher, T.F., and Candinas, R. 2001. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc. Res. 49: 272-280. doi:10.1016/S0008-6363(00)00263-7. PMID:11164837.
50. Dussaule, J.C., and Chatziantoniou, C. 2007. Reversal of renal disease: is it enough to inhibit the action of angiotensin II? Cell Death Differ. 14: 1343-1349. doi:10.1038/sj.cdd.4402143. PMID:17396129.
51. Ebihara, I., Nakamura, T., Tomino, Y., and Koide, H. 1996. Effect of a specific endothelin receptor A antagonist on murine lupus nephritis and IgA nephropathy. Contrib. Nephrol. 118: 155-163. PMID:8744053.
52. A antagonist (BQ-123) inhibits endothelin-1-induced phosphoinositide breakdown and DNA synthesis in rat vascular smooth muscle cells. FEBS Lett. 302: 243-246. doi:10.1016/0014-5793(92)80451-L. PMID:1318228.
53. Ergul, A. 2000. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension, 36: 62-67. PMID:10904013.
54. Ergul, S., Parish, D.C., Puett, D., and Ergul, A. 1996. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension, 28: 652-655. PMID:8843893.
55. Essalihi, R., Dao, H.H., Gilbert, L.A., Bouvet, C., Semerjian, Y., McKee, M.D., and Moreau, P. 2005. Regression of medial elastocalcinosis in rat aorta: a new vascular function for carbonic anhydrase. Circulation, 112: 1628-1635. doi:10.1161/CIRCULATIONAHA.104.528984. PMID:16144999.
56. Evans, N.J., and Walker, J.W. 2007. Dimerization of endothelin receptors: evaluation by CFP/FlAsH FRET and functional consequences. 10th International Conference on Endothelin. Bergamo, Italy. 16-19 September 2007. Abstract O-08. Available from http://www.et-10.it/docs/Abstracts_ET10.pdf. [Accessed 29 May 2008.]
57. Ferreira, S.H., Romitelli, M., and de Nucci, G. 1989. Endothelin-1 participation in overt and inflammatory pain. J. Cardiovasc. Pharmacol. 13(Suppl 5): S220-S222. doi:10.1097/00005344-198900135-00065. PMID:2473319.
58. Floyd, D.M., and Sills, M.A. 2007. PS433540: a dual acting angiotensin and endothelin receptor antagonist. 10th International Conference on Endothelin. Bergamo, Italy. 16-19 September 2007. Abstract O-61. Available from http://www.et-10.it/docs/Abstracts_ET10.pdf. [Accessed 29 May 2008.]
59. Fukunaga, K., Takada, Y., Taniguchi, H., Otsuka, M., Goto, K., and Fukao, K. 1998. Successful liver transplantation from non-heart-beating donors by blockade of endothelin and PAE. Transplant. Proc. 30: 3797. doi:10.1016/S0041-1345(98)01241-X. PMID:9838664.
60. Fukunaga, K., Takada, Y., Taniguchi, H., Mei, G., Seino, K.I., Yuzawa, K., et al. 1999. Endothelin antagonist treatment for successful liver transplantation from non-heart-beating donors. Transplantation, 67: 328-332. doi:10.1097/00007890-199901270-00025. PMID:10075603.
61. Furchgott, R.F., and Zawadzki, J.V. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288: 373-376. doi:10.1038/288373a0.
62. A receptor antagonist on podocyte function and permselective properties of the glomerular barrier in experimental diabetes. 10th International Conference on Endothelin. Bergamo, Italy. 16-19 September 2007. Abstract O-35. Available from http://www.et-10.it/ docs/Abstracts_ET10.pdf. [Accessed 29 May 2008.]
63. Gariepy, C.E., Ohuchi, T., Williams, S.C., Richardson, J.A., and Yanagisawa, M. 2000. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J. Clin. Invest. 105: 925-933. doi:10.1172/JCI8609. PMID:10749572.
64. Ge, Y., Huang, Y., and Kohan, D.E. 2008. Role of the renin-angiotensin- aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure. Can. J. Physiol. Pharmacol. 86: 329-336. doi:10.1139/Y08-028. PMID:18516095.
65. Gijtenbeek, J.M., van den Bent, M.J., and Vecht, C.J. 1999. Cyclosporine neurotoxicity: a review. J. Neurol. 246: 339-346. doi:10.1007/ s004150050360. PMID:10399863.
66. Gordon, M.M., and Madhok, R. 1996. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J. Rheumatol. 23: 788-789. PMID:8730151.
67. Grant, K., Loizidou, M., and Taylor, I. 2003. Endothelin-1: a multifunctional molecule in cancer. Br. J. Cancer, 88: 163-166. doi:10.1038/sj.bjc.6700750. PMID:12610497.
68. Greene, S., Bundey, R.A., Nunley, K., Hartman, J.C., Melvin, L.S., Gorczynski, R.J., et al. 2007. Determination of endothelin receptor antagonist affinities and selectivities in human cardiac membranes. 10th International Conference on Endothelin. Bergamo, Italy. 16-19 September 2007. Abstract P-118. Available from http://www.et-10.it/docs/Abstracts_ET10.pdf. [Accessed 29 May 2008.]
69. Guo, C., and Rabinovitch, M. 1998. A novel chymase cDNA cloned from rat pulmonary artery smooth muscle cells with increased vascular expresion in spontaneously hypertensive rats. Circulation, 98: I-745 (abstract).
70. Hall, J.E. 1994. Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension, 23: 381-394. PMID:8125566.
71. Henness, S., and Wigley, F.M. 2007. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr. Opin. Rheumatol. 19: 611-618. doi:10.1097/BOR.0b013e3282f13137. PMID:17917543.
72. Hickey, K.A., Rubanyi, G.M., Paul, R.J., and Highsmith, R.F. 1985. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 248: C550-C556. PMID:3993773.
73. Hillier, C., Berry, C., Petrie, M.C., O'Dwyer, P.J., Hamilton, C., Brown, A., and McMurray, J. 2001. Effects of urotensin II in human arteries and veins of varying caliber. Circulation, 103: 1378-1381. PMID:11245639.
74. Hocher, B., Thöne-Reinecke, C., Rohmeiss, P., Schmager, F., Slowinski, R., Burst, V., et al. 1997. Endothelin-1 transgenic mice develop glomerulosclerosis, intersitial fibrosis, and renal cysts but not hypertension. J. Clin. Invest. 99: 1380-1389. doi:10.1172/JCI119297. PMID:9077548.
75. Hoeper, M.M., Seyfarth, H.J., Hoeffken, G., Wirtz, H., Spiekerkoetter, E., Pletz, M.W., et al. 2007. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur. Respir. J. 30: 1096-1102. doi:10.1183/09031936.00032407. PMID:17652314.
76. A-receptor anatagonist, reduces proteinuria in patients with diabetes mellitus. In Regulation of Vascular Tone in Humans by Endothelium-derived Mediators [thesis]. Utrecht, The Netherlands: Elinkwijk BV: pp. 89-102.
77. Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., and Chaudhuri, G. 1987. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84: 9265-9269. doi:10.1073/pnas.84.24.9265. PMID:2827174.
78. Ikeda, K., Emoto, N., Raharjo, S.B., Nurhantari, Y., Saiki, K., Yokoyama, M., and Matsuo, M. 1999. Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J. Biol. Chem. 274: 32469-32477. doi:10.1074/jbc.274.45.32469. PMID:10542292.
79. Iwasa, S., Fan, J., Miyauchi, T., and Watanabe, T. 2001. Blockade of endothelin receptors reduces diet-induced hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice. Pathobiology, 69: 1-10. doi:10.1159/000048751. PMID:11641611.
80. Julkunen, H., Saijonmaa, O., Gronhagen-Riska, C., Teppo, A.M., and Fyhrquist, F. 1991. Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann. Rheum. Dis. 50: 526-527. PMID:1877866.
81. Kaisers, U., Busch, T., Wolf, S., Lohbrunner, H., Wilkens, K., Hocher, B., and Boemke, W. 2000. Inhaled endothelin A antagonist improves arterial oxygenation in experimental acute lung injury. Intensive Care Med. 26: 1334-1342. doi:10.1007/s001340000608. PMID:11089761.
82. A receptor antagonist LU-135252 selectively attenuates hypoxic pulmonary vasoconstriction. Am. J. Physiol. 294: R601-R605.
83. A receptor antagonist attenuates pulmonary inflammation in experimental acute lung injury. 10th International Conference on Endothelin. Bergamo, Italy. 16-19 September 2007. Abstract O-29. Available from http://www.et-10.it/docs/Abstracts_ET10.pdf. [Accessed 29 May 2008.]
84. Katoh, T., Chang, H., Uchida, S., Okuda, T., and Kurokawa, K. 1990. Direct effects of endothelin in the rat kidney. Am. J. Physiol. 258: F397-F402. PMID:2137984.
85. Kaye, D.M., and Krum, H. 2007. Drug discovery for heart failure: a new era or the end of the pipeline? Nat. Rev. Drug Discov. 6: 127-139. doi:10.1038/nrd2219. PMID:17268484.
86. Kedzierski, R.M., and Yanagisawa, M. 2001. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41: 851-876. doi:10.1146/annurev.pharmtox.41.1.851. PMID:11264479.
87. Kelland, N.F., and Webb, D.J. 2006. Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp. Biol. Med. (Maywood), 231: 696-699. PMID:16740982.
88. Kelland, N.F., and Webb, D.J. 2007. Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart, 93: 2-4. doi:10.1136/hrt.2006.089250. PMID:17170334.
89. Kiowski, W., Sutsch, G., Hunziker, P., Muller, P., Kim, J., Oechslin, E., et al. 1995. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet, 346: 732-736. doi:10.1016/S0140-6736(95) 91504-4. PMID:7658874.
90. Kirchengast, M., and Luz, M. 2005. Endothelin receptor antagonists: clinical realities and future directions. J. Cardiovasc. Pharmacol. 45: 182-191. doi:10.1097/01.fjc.0000152030.61620.57. PMID:15654268.
91. Kirkby, N.S., Hadoke, P.W., Bagnall, A.J., and Webb, D.J. 2008. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br. J. Pharmacol. 153: 1105-1119. doi:10.1038/sj.bjp.0707516. PMID:17965745.
92. Ko, C., Gieske, M.C., Al-Alem, L., Hahn, Y., Su, W., Gong, M.C., et al. 2006. Endothelin-2 in ovarian follicle rupture. Endocrinology, 147: 1770-1779. doi:10.1210/en.2005-1228. PMID:16410304.
93. Ko, C.J., Na, G., Koo, Y., and Bridges, P. 2007. Endothelin-2 (EDN2) in ovarian follicle rupture and oocyte transport. 10th International Conference on Endothelin. Bergamo, Italy. 16-19 September 2007. Abstract O-10. Available from http://www.et-10.it/docs/Abstracts_ET10.pdf. [Accessed 29 May 2008.]
94. Kohan, D.E. 1997. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 29: 2-26. doi:10.1016/S0272-6386(97)90004-4. PMID:9002526.
95. Kohan, D.E. 2006. The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr. Opin. Nephrol. Hypertens. 15: 34-40. PMID:16340664.
96. Korn, J.H., Mayes, M., Matucci Cerinic, M., Rainisio, M., Pope, J., Hachulla, E., et al. 2004. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50: 3985-3993. doi:10.1002/art.20676. PMID:15593188.
97. Krum, H., Viskoper, R.J., Lacourciere, Y., Budde, M., and Charlon, V. 1998. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med. 338: 784-790. doi:10.1056/NEJM199803193381202. PMID:9504938.
98. Lattmann, T., Hein, M., Horber, S., Ortmann, J., Teixeira, M.M., Souza, D.G., et al. 2005. Activation of pro-inflammatory and antiinflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling. Am. J. Transplant. 5: 1042-1049. doi:10.1111/j.1600-6143.2005. 00807.x. PMID:15816884.
99. Lee, T.M., Chen, C.C., Lin, M.S., and Chang, N.C. 2008. Effect of endothelin receptor antagonists on ventricular susceptibility in post-infarcted rats. Am. J. Physiol. Heart Circ. Physiol. 294: H1871-H1879. doi:10.1152/ajpheart.01129.2007. PMID:18281380.
100. Lerman, A., Edwards, B.S., Hallett, J.W., Heublein, D.M., Sandberg, S.M., and Burnett, J.C., Jr. 1991. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325: 997-1001. PMID:1886637.
101. Leuchte, H.H., Meis, T., El-Nounou, M., Michalek, J., and Behr, J. 2008. Inhalation of endothelin receptor blockers in pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L772-L777. doi:10.1152/ajplung. 00405.2007. PMID:18296497.
102. Lteif, A., Vaishnava, P., Baron, A.D., and Mather, K.J. 2007. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes, 56: 728-734. doi:10.2337/db06-1406. PMID:17327443.
103. Luft, F.C. 2002. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr. Opin. Nephrol. Hypertens. 11: 59-66. doi:10.1097/00041552-200201000- 00009. PMID:11753088.
104. Luscher, T.F., and Barton, M. 2000. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 102: 2434-2440. PMID:11067800.
105. Maguire, J.J., and Davenport, A.P. 2002. Is urotensin-II the new endothelin? Br. J. Pharmacol. 137: 579-588. doi:10.1038/sj.bjp.0704924. PMID:12381671.
106. Makita, T., Sucov, H.M., Gariepy, C.E., Yanagisawa, M., and Ginty, D.D. 2008. Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons. Nature, 452: 759-763. doi:10.1038/nature06859. PMID:18401410.
107. Mann, J., Wenzel, R.R., Juergens, C., Bruck, H., Philipp, T., and Mitchell, A. 2006. Avosentan, a selective endothelin receptor antagonist, decreases albuminuria in patients with diabetic nephropathy. Forefronts in Nephrology: Endothelial Biology and Renal Disease: from the bench to prevention. New York, USA. 16-19 March 2006. Abstract 6. Available from http://www.associationhq.com/isn/forefronts/pdf/abstractsNY/9.pdf. [Accessed 13 July 2008.]
108. Masaki, T. 1998. The discovery of endothelins. Cardiovasc. Res. 39: 530-533. doi:10.1016/S0008-6363(98)00153-9. PMID:9861293.
109. Maurer, M., Wedemeyer, J., Metz, M., Piliponsky, A.M., Weller, K., Chatterjea, D., et al. 2004. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature, 432: 512-516. doi:10.1038/ nature03085. PMID:15543132.
110. Mayes, M.D. 2003. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum. 48: 1190-1199. doi:10.1002/art.10895. PMID:12746891.
111. Miyauchi, T., and Goto, K. 1999. Heart failure and endothelin receptor antagonists. Trends Pharmacol. Sci. 20: 210-217. doi:10.1016/S0165- 6147(99)01297-3. PMID:10354617.
112. Miyauchi, T., Yanagisawa, M., Tomizawa, T., Sugishita, Y., Suzuki, N., Fujino, M., et al. 1989. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet, 2: 53-54. doi:10.1016/S0140-6736(89)90303-6. PMID:2567834.
113. Morigi, M., Buelli, S., Angioletti, S., Zanchi, C., Longaretti, L., Zoja, C., et al. 2005. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am. J. Pathol. 166: 1309-1320. PMID:15855633.
114. Morigi, M., Buelli, S., Zanchi, C., Longaretti, L., Macconi, D., Benigni, A., et al. 2006. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am. J. Pathol. 169: 1965-1975. doi:10.2353/ajpath.2006.051331. PMID:17148661.
115. Mundy, A.L., Haas, E., Bhattacharya, I., Widmer, C.C., Kretz, M., Hofmann-Lehmann, R., et al. 2007. Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: implications for diet-induced obesity. Cardiovasc. Res. 73: 368-375. doi:10.1016/j.cardiores.2006.11. 019. PMID:17166491.
116. Nakamura, T., Ebihara, I., Tomino, Y., and Koide, H. 1995. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int. 47: 481-489. doi:10.1038/ki.1995.61. PMID:7723234.
117. Nakov, R., Pfarr, E., and Eberle, S. 2002. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am. J. Hypertens. 15: 583-589. doi:10.1016/S0895-7061(02) 02933-3. PMID:12118903.
118. Nett, P.C., Teixeira, M.M., Candinas, D., and Barton, M. 2006. Recent developments on endothelin antagonists as immunomodulatory drugs: from infection to transplantation medicine. Recent Patents Cardiovasc. Drug Discov. 1: 265-276.
119. O'Brien, R.F., Robbins, R.J., and McMurtry, I.F. 1987. Endothelial cells in culture produce a vasoconstrictor substance. J. Cell. Physiol. 132: 263-270. doi:10.1002/jcp.1041320210. PMID:3114270.
120. Ohuchi, T., Yanagisawa, M., and Gariepy, C.E. 2000. Renal tubular effects of endothelin-B receptor signaling: its role in cardiovascular homeostasis and extracellular volume regulation. Curr. Opin. Nephrol. Hypertens. 9: 435-439. doi:10.1097/00041552-200007000-00016. PMID:10926181.
121. Omland, T., Lie, R.T., Aakvaag, A., Aarsland, T., and Dickstein, K. 1994. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation, 89: 1573-1579. PMID:8149523.
122. Opocensky, M., Dvorak, P., Maly, J., Kramer, H.J., Backer, A., Kopkan, L., et al. 2004. Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats. Physiol. Res. 53: 581-593. PMID:15588125.
123. Opocensky, M., Kramer, H.J., Backer, A., Vernerova, Z., Eis, V., Cervenka, L., et al. 2006. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension, 48: 965-971. doi:10.1161/01.HYP.0000245117.57524.d6. PMID:17015777.
124. A receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J. Am. Soc. Nephrol. 10: 387-391. PMID:10215340.
125. Orth, S.R., Odoni, G., Karkoszka, H., Ogata, H., Viedt, C., Amann, K., et al. 2003. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models. Nephrol. Dial. Transplant. 18: 62-69. doi:10.1093/ndt/18.1.62. PMID:12480961.
126. Ortmann, J., Amann, K., Brandes, R.P., Kretzler, M., Munter, K., Parekh, N., et al. 2004. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension, 44: 974-981. doi:10.1161/01.HYP.0000149249.09147.b4. PMID:15545511.
127. Ortmann, J., Nett, P.C., Celeiro, J., Traupe, T., Tornillo, L., Hofmann-Lehmann, R., et al. 2005. Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells. Biochem. Biophys. Res. Commun. 334: 689-695. doi:10.1016/j.bbrc.2005.06.140. PMID:16009335.
128. Pacher, R., Stanek, B., Hulsmann, M., Koller-Strametz, J., Berger, R., Schuller, M., et al. 1996. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. 27: 633-641. doi:10.1016/0735-1097(95) 00520-X. PMID:8606275.
129. Parrinello, G., Scaglione, R., Pinto, A., Corrao, S., Cecala, M., Di Silvestre, G., et al. 1996. Central obesity and hypertension: the role of plasma endothelin. Am. J. Hypertens. 9: 1186-1191. doi:10.1016/S0895-7061(96) 00259-2. PMID:8972889.
130. Pisoni, R., Ruggenenti, P., and Remuzzi, G. 2001. Renoprotective therapy in patients with nondiabetic nephropathies. Drugs, 61: 733-745. doi:10.2165/00003495-200161060-00003. PMID:11398906.
131. Placier, S., Boffa, J.J., Dussaule, J.C., and Chatziantoniou, C. 2006. Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice. Nephrol. Dial. Transplant. 21: 881-888. doi:10.1093/ndt/gfk004. PMID:16384829.
132. Pollock, D.M., and Schneider, M.P. 2006. Clarifying endothelin type B receptor function. Hypertension, 48: 211-212. doi:10.1161/01.HYP. 0000229908.62191.6e. PMID:16801483.
133. Proven, A., Roderick, H.L., Conway, S.J., Berridge, M.J., Horton, J.K., Capper, S.J., and Bootman, M.D. 2006. Inositol 1,4,5-trisphosphate supports the arrhythmogenic action of endothelin-1 on ventricular cardiac myocytes. J. Cell Sci. 119: 3363-3375. doi:10.1242/jcs.03073. PMID:16882691.
134. Puri, A., McGoon, M.D., and Kushwaha, S.S. 2007. Pulmonary arterial hypertension: current therapeutic strategies. Nat. Clin. Pract. Cardiovasc. Med. 4: 319-329. doi:10.1038/ncpcardio0890. PMID:17522721.
135. Rachdaoui, N., and Nagy, L.E. 2003. Endothelin-1-stimulated glucose uptake is desensitized by tumor necrosis factor-alpha in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 285: E545-E551. PMID:12773307.
136. Remuzzi, G., Perico, N., and Benigni, A. 2002. New therapeutics that antagonize endothelin: promises and frustrations. Nat. Rev. Drug Discov. 1: 986-1001. doi:10.1038/nrd962. PMID:12461520.
137. Rich, S., and McLaughlin, V.V. 2003. Endothelin receptor blockers in cardiovascular disease. Circulation, 108: 2184-2190. doi:10.1161/01.CIR. 0000094397.19932.78. PMID:14597580.
138. Rubanyi, G.M., and Polokoff, M.A. 1994. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46: 325-415. PMID:7831383.
139. Rubanyi, G.M., and Vanhoutte, P.M. 1985. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J. Physiol. 364: 45-56. PMID:3861856.
140. Rubin, L.J., Badesch, D.B., Barst, R.J., Galie, N., Black, C.M., Keogh, A., et al. 2002. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346: 896-903. doi:10.1056/NEJMoa012212. PMID:11907289.
141. Rubin, L.J., Hoeper, M.M., Klepetko, W., Galie, N., Lang, I.M., and Simonneau, G. 2006. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc. Am. Thorac. Soc. 3: 601-607. doi:10.1513/pats.200605-111LR. PMID:16963541.
142. B receptor antagonist) on metabolic changes during stress and diabetes. Pharmacol. Res. 51: 107-115. doi:10.1016/j.phrs. 2004.05.009. PMID:15629255.
143. Sakai, S., Miyauchi, T., Kobayashi, M., Yamaguchi, I., Goto, K., and Sugishita, Y. 1996. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature, 384: 353-355. doi:10.1038/384353a0. PMID:8934519.
144. Sam, F., and Colucci, W.S. 1999. Role of endothelin-1 in myocardial failure. Proc. Assoc. Am. Physicians, 111: 417-422. PMID:10519162.
145. Schiffrin, E.L. 1999. State-of-the-Art lecture. Role of endothelin-1 in hypertension. Hypertension, 34: 876-881. PMID:10523377.
146. Schiffrin, E.L. 2001. Role of endothelin-1 in hypertension and vascular disease. Am. J. Hypertens. 14: 83S-89S. doi:10.1016/S0895-7061(01)02074- X. PMID:11411770.
147. Schiffrin, E.L. 2002. Beyond blood pressure: the endothelium and atherosclerosis progression. Am. J. Hypertens. 15: 115S-122S. doi:10.1016/S0895-7061(02)03006-6. PMID:12383592.
148. Schiffrin, E.L. 2005. Vascular endothelin in hypertension. Vascul. Pharmacol. 43: 19-29. doi:10.1016/j.vph.2005.03.004. PMID:15955745.
149. Schneider, M.P., Ge, Y., Pollock, D.M., Pollock, J.S., and Kohan, D.E. 2008. Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension, 51: 1605-1610. doi:10.1161/HYPERTENSIONAHA.107.108126. PMID:17998477.
150. Seyrantepe, V., Hinek, A., Junzheng, P., Fedjaev, M., Ernest, S., Kadota, Y., et al. 2008. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation, 117: 1973-1981. doi:10.1161/CIRCULATIONAHA. 107.733212. PMID:18391110.
151. Sfikakis, P.P., Papamichael, C., Stamatelopoulos, K.S., Tousoulis, D., Fragiadaki, K.G., Katsichti, P., et al. 2007. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 56: 1985-1993. doi:10.1002/art.22634. PMID:17530638.
152. Shapiro, S. 2003. Management of pulmonary hypertension resulting from interstitial lung disease. Curr. Opin. Pulm. Med. 9: 426-430. doi:10.1097/00063198-200309000-00015. PMID:12904715.
153. Shennib, H., Lee, A.G., Kuang, J.Q., Yanagisawa, M., Ohlstein, E.H., and Giaid, A. 1998. Efficacy of administering an endothelin-receptor antagonist (SB209670) in ameliorating ischemia-reperfusion injury in lung allografts. Am. J. Respir. Crit. Care Med. 157: 1975-1981. PMID:9620935.
154. Souza-Rodrigues, R.D., Costa, A.M., Lima, R.R., Dos Santos, C.D., Picanco-Diniz, C.W., and Gomes-Leal, W. 2008. Inflammatory response and white matter damage after microinjections of endothelin-1 into the rat striatum. Brain Res. 1200: 78-88. doi:10.1016/j.brainres.2007.11.025.
155. Speedel. 2007. Pipeline Decisions SPP301 and SPP 200. ASCEND Phase III clinical results. Webcast 23 October 2007. Available from http://www.speedel. com/section/6/subsections/8. [accessed 13 July 2008.]
156. Staniloae, C., Dupuis, J., White, M., Gosselin, G., Dyrda, I., Bois, M., et al. 2004. Reduced pulmonary clearance of endothelin in congestive heart failure: a marker of secondary pulmonary hypertension. J. Card. Fail. 10: 427-432. doi:10.1016/j.cardfail.2004.01.008. PMID:15470654.
157. Sutsch, G., and Barton, M. 1999. Endothelin in heart failure. Curr. Hypertens. Rep. 1: 62-68. doi:10.1007/s11906-999-0075-9. PMID:10981044.
158. Tang, J.L., Aitouche, A., Subbotin, V., Salam, A., Sun, H., Gandhi, C., et al. 1999. Endothelin-1 receptor blockade and its effect on chronic rejection. Transplant. Proc. 31: 1249. doi:10.1016/S0041-1345(98)01983-6. PMID:10083558.
159. Tepe, G., Brehme, U., Seeger, H., Raschack, M., Claussen, C.D., and Duda, S.H. 2002. Endothelin A receptor antagonist LU 135252 inhibits hypercholesterolemia-induced, but not deendothelialization-induced, atherosclerosis in rabbit arteries. Invest. Radiol. 37: 349-355. doi:10.1097/00004424-200206000-00007. PMID:12021592.
160. Tomobe, Y., Miyauchi, T., Saito, A., Yanagisawa, M., Kimura, S., Goto, K., and Masaki, T. 1988. Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats. Eur. J. Pharmacol. 152: 373-374. doi:10.1016/0014-2999(88)90736-4. PMID:3065091.
161. Traupe, T., Lang, M., Goettsch, W., Munter, K., Morawietz, H., Vetter, W., and Barton, M. 2002. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J. Hypertens. 20: 2239-2245. doi:10.1097/00004872-200211000-00024. PMID:12409963.
162. Uchida, Y., Ninomiya, H., Saotome, M., Nomura, A., Ohtsuka, M., Yanagisawa, M., et al. 1988. Endothelin, a novel vasoconstrictor peptide, as potent bronchoconstrictor. Eur. J. Pharmacol. 154: 227-228. doi:10.1016/0014-2999(88)90106-9. PMID:3068063.
163. van Harmelen, V., Eriksson, A., Astrom, G., Wahlen, K., Naslund, E., Karpe, F., et al. 2008. Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. Diabetes, 57: 378-386. doi:10.2337/db07-0893. PMID:18025413.
164. Verhaar, M.C., Strachan, F.E., Newby, D.E., Cruden, N.L., Koomans, H.A., Rabelink, T.J., and Webb, D.J. 1998. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation, 97: 752-756. PMID:9498538.
165. Vetter, D., Shaw, S.G., Brandes, R.P., Munter, K., Vetter, W., and Barton, M. 2006. Beneficial cardiovascular effects of endothelin ET(A) receptor blockade in established long-term heart failure after myocardial infarction. Exp. Biol. Med. (Maywood), 231: 857-860. PMID:16741012.
166. Virdis, A., and Schiffrin, E.L. 2003. Vascular inflammation: a role in vascular disease in hypertension? Curr. Opin. Nephrol. Hypertens. 12: 181-187. doi:10.1097/00041552-200303000-00009. PMID:12589179.
167. A-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. ASN Renal Week 2005 (Abstract F-FC093).
168. Wesson, D.E. 2006. Regulation of kidney acid excretion by endothelins. Kidney Int. 70: 2066-2073. PMID:17021604.
169. A receptor in 3T3-L1 adipocytes. J. Biol. Chem. 274: 8103-8110. doi:10.1074/jbc.274.12.8103. PMID:10075711.
170. Yamane, K., Kashiwagi, H., Suzuki, N., Miyauchi, T., Yanagisawa, M., Goto, K., and Masaki, T. 1991. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum. 34: 243-244. doi:10.1002/art. 1780340220. PMID:1994925.
171. Yanagisawa, M., and Masaki, T. 1989. Molecular biology and biochemistry of the endothelins. Trends Pharmacol. Sci. 10: 374-378. doi:10.1016/0165-6147(89)90011-4. PMID:2690429.
172. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., et al. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332: 411-415. doi:10.1038/332411a0. PMID:2451132.
173. Yanagisawa, H., Hammer, R.E., Richardson, J.A., Emoto, N., Williams, S.C., Takeda, S., et al. 2000. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J. Clin. Invest. 105: 1373-1382. doi:10.1172/JCI7447. PMID:10811845.
174. Yokokawa, K., Tahara, H., Kohno, M., Murakawa, K., Yasunari, K., Nakagawa, K., et al. 1991. Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann. Intern. Med. 114: 213-215. PMID:1984746.
175. Yoshio, T., Masuyama, J., Mimori, A., Takeda, A., Minota, S., and Kano, S. 1995. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann. Rheum. Dis. 54: 361-365. PMID:7794041.
176. Zanatta, C.M., Gerchman, F., Burttet, L., Nabinger, G., Jacques-Silva, M.C., Canani, L.H., and Gross, J.L. 2008. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 80: 299-304. doi:10.1016/j.diabres.2007.12.024. PMID:18346810.